Every material Form 8-K TG Therapeutics filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
TG Therapeutics reported third quarter 2025 total revenue of $161.7 million, up from $83.9 million a year earlier, and net income of $390.9 million, which includes a non-recurring income tax benefit of approximately $365.0 million. The company raised its full-year 2025 BRIUMVI U.S. net product revenue target to approximately $585 million and its global revenue target to approximately $600 million, and authorized a new $100 million share repurchase program.
Q3 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million, versus $83.9 million total revenue in Q3 2024
Net income of $390.9 million, including a non-recurring income tax benefit of approximately $365.0 million; operating income was $29.4 million
Full-year 2025 BRIUMVI U.S. net product revenue target raised to approximately $585 million from $570-$575 million; global revenue target raised to approximately $600 million from $585 million
Completed the prior $100 million share repurchase, buying about 3.5 million shares at an average $28.55; new $100 million program authorized
TG Therapeutics reported second quarter 2025 total revenue of $141.1 million, up from $73.5 million a year earlier, and net income of $28.2 million, compared with $6.9 million. The company raised its full-year 2025 BRIUMVI U.S. net revenue target to $570 million to $575 million from $560 million, and its total global revenue target to approximately $585 million from $575 million.
Q2 2025 BRIUMVI U.S. net product revenue was $138.8 million, up 91% from the same period last year.
Full-year 2025 BRIUMVI U.S. net revenue target raised to $570 million to $575 million, from $560 million.
Full-year 2025 total global revenue target raised to approximately $585 million, from $575 million.
Cash, cash equivalents and investment securities were $278.9 million as of June 30, 2025.
TG Therapeutics reported first quarter 2025 total revenue of $120.9 million, up from $63.5 million a year earlier, and net income of $5.1 million compared with a net loss of $10.7 million. The company raised its full-year 2025 BRIUMVI U.S. net product revenue target to $560 million and its global revenue target to $575 million.
Total revenue of $120.9 million for the three months ended March 31, 2025, versus $63.5 million a year earlier
Net income of $5.1 million, or $0.03 per diluted share, versus a net loss of $10.7 million in the prior-year quarter
Full-year 2025 BRIUMVI U.S. net product revenue target raised to $560 million from $525 million; global revenue target raised to $575 million from $540 million
Total research and development expense rose to $46.4 million and selling, general and administrative expense to $50.3 million
TG Therapeutics reported fourth-quarter and full-year 2024 results, with full-year total revenue of $329.0 million and net income of $23.4 million, compared with $233.7 million and $12.7 million in 2023. The company set a 2025 target of approximately $540 million in total global revenue and said its $311.0 million in cash, cash equivalents and investment securities, combined with projected BRIUMVI revenue, should fund the business under its current operating plan.
Q4 2024 total revenue was $108.2 million, compared with $44.0 million in Q4 2023; Q4 2024 net income was $23.3 million, compared with a net loss of $14.4 million.
Full-year 2024 total revenue was $329.0 million, compared with $233.7 million in 2023; 2023 included recognition of a one-time $140.0 million Neuraxpharm upfront payment.
2025 target total global revenue is approximately $540 million, including BRIUMVI U.S. net product revenue of approximately $525 million.
Cash, cash equivalents and investment securities were $311.0 million as of December 31, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every TG Therapeutics filing is on SEC EDGAR ↗. 8-K briefs of other companies →